← DaVita HealthCare Partners overview

DaVita HealthCare Partners vs Chemed: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

DaVita HealthCare Partners Inc (DVA)

Q3 2026
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

July 2026
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

Latest
▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

  • Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.

    This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.

  • Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.

    Guidance raise and buybacks are direct positive catalysts for the stock.

  • Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.

    This explains the negative price reaction despite headline beats.

  • Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.

    This is the key reason for the sharp negative price move after earnings.

Chemed Corp (CHE)

Q3 2026
▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

  • Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.

    This is the core new event that directly lifts earnings expectations and the stock.

  • Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.

    Explains the operational engine behind the earnings beat and the one soft spot investors should watch.

  • Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.

    Shows a concrete new capital return action that supports the shares.

  • Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.

    Provides the main negative view that balances the positive earnings news.

August 2026
▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

  • Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.

    This is the core new event that directly lifts earnings expectations and the stock.

  • Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.

    Explains the operational engine behind the earnings beat and the one soft spot investors should watch.

  • Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.

    Shows a concrete new capital return action that supports the shares.

  • Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.

    Provides the main negative view that balances the positive earnings news.

Latest
▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

  • Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.

    This is the core new event that directly lifts earnings expectations and the stock.

  • Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.

    Explains the operational engine behind the earnings beat and the one soft spot investors should watch.

  • Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.

    Shows a concrete new capital return action that supports the shares.

  • Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.

    Provides the main negative view that balances the positive earnings news.